The European Commission amends the marketing authorization for Celgene's (CELG -0.2%) REVLIMID to include patients with MDS-related transfusion-dependent anemia when other treatments have failed or proven insufficient. The company has pursued clearance for the indication for some 7 years. (previous)
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blogat Zacks.com (Thu, 11:07AM)
at Nasdaq.com (Tue, 2:12PM)
at Zacks.com (Mon, 6:20PM)
at Benzinga.com (Sun, 8:57PM)
at Zacks.com (Fri, 2:30PM)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs